1.5100
10-一月-25 15:45:00
15 分钟延时
股票
+0.0600
+4.14%
今日范围
1.4100 - 1.5300
ISIN
N/A
来源
NASDAQ
Cue Biopharma Initiates Patient Dosing in Phase 1 Study of CUE-101 in Combination with KEYTRUDA® (pembrolizumab) as First-line Treatment for HPV+ Recurrent/Metastatic Head and Neck Cancer
08 2月 2021 07:00:01 条件 Nasdaq GlobeNewswire